Cyprotex Share Discussion Threads

[husbod] 12/8/2016 12:31

Hi p1nkfish.

Some of these RNSs seem to suggest that CRX is buying its own shares - is that right?

[p1nkfish] 11/8/2016 20:09

North Atlantic Smaller Co's has Trident as constituent.
Also in EKF and SBS.
Worth considering. NAS.
TER is not the lowest but Chris Mills has a good hand on steering the trust and it should see benefit from crx, sbs and ekf amongst others.

[deadly] 02/8/2016 13:01

I might break even on this soon.
Bought at the equivalent of 201p 12 years ago!

Had almost given up on it.

[p1nkfish] 02/8/2016 12:56

Trident benefit if crx continue as is. Hence, they are on board.

[rrb] 02/8/2016 10:04

And remember any liability from loan notes can be used to offset future tax...

[husbod] 02/8/2016 09:44

All good stuff.

Interested by the three elements of the strategic view in that the Loan Notes are not one of them.

The Loan Notes issue seems to have died down partly on the basis of the share price of 110p at the relevant date but mainly I assume because of the undertakings/support by Trident. The former must now be treated with caution given the current share price and obviously a major change in Trident's overall situation could cause a problem as their undertaking only relates to the normal course of events.

It's probably safe to assume that there will be no further announcements on the Loan Notes whilst Trident stay on board but I'll be glad when they crystallise and this particular issue will no longer arise.

In the meantime the company can concentrate on what it is doing so well namely growing the products and growing the revenue. Acquisitions could still occur but clearly organic growth is the priority.

[saltaire111] 02/8/2016 09:41

The margin is astonishing. And huge growth potential. Excellent results but I really do believe this is just the start.

Ok, in know it's a board cliche, but I can see this one doubling or even trebling. Oh hang on, it already has!!!!

Salty.

[rrb] 02/8/2016 09:15

The fact that trident is very supportive is a massive positive.

[rrb] 02/8/2016 09:11

Excellent! Revs of >£15m for full year with a gross margin of 77% and Macap of £33m?!!

[p1nkfish] 02/8/2016 08:44

Pleasing to read. Well done all at CRX.

Recent sellers may be somewhat annoyed but the fact is management have let the market know they couldn't forecast because growth was running away from them, positively. They have done that more than once sequentially.

Hold your winners.

I can't see a downturn in business levels here yet. Might flatten but not reverse yet so what's a reason to sell?

A great little British company and earns some in $s too.

SBS now private, moved into Sherwood - Mills as one protagonist.

[battlebus2] 02/8/2016 08:09

Excellent results and the market also like them with another 10p rise to start :))

[this_is_me] 02/8/2016 08:02

It has already shot up since I bought my first small holding in 2013 ( added to since). The important point is that will be much higher in a few years time, assuming all goes well.

[chadders] 02/8/2016 07:48

Stellar results. She's gonna blow!

[saltaire111] 02/8/2016 07:32

Superb results

Salty

[skinny] 02/8/2016 07:31

Revenue growth and increase in profitability continue into 2016

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today reports its interim results for the half year to 30 June 2016.


Financial Highlights

· Revenues up 26% to £8.73 million (H1 2015: £6.93 million).
· Gross margins were 77.5% (H1 2015: 76.8%).
· Operating profit up significantly to £1.49 million (H1 2015: £0.36 million).
· Underlying EBITDA^ increased to £2.34 million (H1 2015: £1.10 million).
· Cash of £6.82 million (H1 2015: £4.13 million, FY 2015: £5.41 million).

^ excluding share based payment charge of £0.13 million (H1 2015: £0.08 million)

Operational Highlights

· Significant increase in new customers to 139 (H1 2015: 103).
· Watertown revenues in H1 2016, up almost 70% from the comparative period, benefitting from the general improvement in the investment environment in the East Coast of USA.
· Demand for high value drug-drug interaction packages and metabolite identification has been strong and has assisted in growing revenues ahead of expectations.
· Our presence at Alderley Park BioHub site has increased with the opening of a new bioanalytical laboratory to allow for planned expansion of these services later in the year and the expansion our toxicology facility. Proprietary 3D cellular models have been highly successful in revenue generation.
· Validation of a High Throughput (HT) ADME screening platform at our Watertown site has been completed and is supporting large scale screening contracts for the US Government and other customers.
· Upgrading of our toxicology assays at Kalamazoo to provide in vitro GLP genotoxicity services has already seen positive customer interest.
· Website upgrades and social media engagement have increased the global recognition of the Cyprotex brand.
· Revenue from the largest customer accounts for 10.3% (FY 2015: 9.6%) of total revenue and represents continuing business with a major pharmaceutical company.

Ian Johnson, Chairman of Cyprotex PLC, said:

"I am delighted to report that the progress made in 2015 has continued into 2016 and, as previously flagged to the market, we are substantially ahead of our expectations. The growth of the business is global and from an increasingly wide range of industries and sectors. Investment in all sites, which commenced in 2014, continues and is delivering high quality new services which contributed to the increase in revenue in H1 2016. Watertown and both UK sites have grown revenues and consequently operational profitability. The Kalamazoo site has received considerable investment to launch a suite of GLP genotoxicity services which we expect will drive revenue growth for the site in the second half of the year. Of note is the collaboration with Cytocentrics announced in February 2016 where we are developing a full range of ion channel services to meet the expected regulatory changes in cardiac safety testing as a consequence of the CiPA initiative. The second half has started well and the Board looks forward to the remainder of the year with continued confidence."

This announcement contains inside information for the purposes of Article 7 of EU regulation 596/2014.

[bahiflyer] 01/8/2016 22:35

Good choice Salty. I expect tomorrow's interims to be sparkling to say the least. Operating profit of possibly £4M maybe more depending on how profitable Watertown & Kalamazoo have gotten.

[saltaire111] 01/8/2016 22:16

Bought some more today. backing a winner.

Salty

[p1nkfish] 01/8/2016 18:02

Interim were 18th Aug last year.
About time we had some idea of the review outcome too.

[husbod] 27/7/2016 09:42

Is that a politicians "one-off" buywell. Bet you wont be able to resist a further post when we get some big news such as the outcome of the loan note deliberations. Or are you no longer a share-holder?

Don't worry, I don't expect a reply but am looking forward to your next "one-off".

[battlebus2] 27/7/2016 08:52

Moving back up today :))

[husbod] 24/7/2016 18:24

Good to have your thoughts B.

Any idea if the guys at the top of CRX and SBS know each other?

I know absolutely nothing about SBS and do not have the time to research it but one obvious implication of your post would be the benefit of a friendly merger of the two companies or a take-over by CRX of SBS.

Those on this bb who know SBS far better than me might well say that this is an absurd idea and that any such relationship is the last thing CRX should consider.

Any thoughts guys?

200p seems a bit of a modest take out price B.

[p1nkfish] 24/7/2016 16:58

But SBS is likely to be taken out soon and private via Chris Mills.

[deadly] 23/7/2016 08:51

FYI:
buywell2 23 Jul'16 - 01:18 - 37 of 37 0 0 edit

I suggest you all read the latest annual report on the company website

There is a hidden nugget within which my take means Cyprotex have a decent large contract is now underway with a large Pharma , I know which one but it would not be prudent to say which one it was . These BIG Pharmas do NOT want their business aired in public so have told Cyprotex to stay quiet ie no RNS

My gut tells me a predator/s are now looking at both SBS and CRX

Current exchange rate moves have made a purchase now cheaper for those outside
the UK

One of them might want part of SBS but not the whole

Likewise with CRX

One of them might want CRX with part of SBS as an add on to include molecular diagnostics and DNA sequencing to CRX services which have expanded at a very fast clip of late.

What we must hope for is that a move is not made before the interims are released as they will make a buyout price in excess of 200p possible in 2017

What I also hope will happen is that the BIG Pharma will be the one to buy CRX when another foreign offer is made , I also think I know who that will be.

My take is that the BIG Pharma might even want BOTH Cyprotex and Source Bioscience to become one company as such a combination would enhance their Personalized Medicine aspirations plus gain a better foothold in the UK and NHS market (via SBS)

So on the whole my hopes and dreams for the 2 companies remain

What price a CRX/SBS combine would be would be interesting to ponder

There would be savings and cross selling benefits to be made

A profit of 10M within 3 years from such a combine as work from the USA looks set to rocket due to recent EPA workload and USA chemical testing law changes meaning more Toxicology and Endocrine Disruptor testing looks undemanding

A buyout price for such a business then would be in the region of 250 Million pounds

Can the BODS of both companies see the logic ?

Can the major shareholders make them if the don't ?

We will soon find out

[buywell2] 23/7/2016 01:22

POST REMOVED

[buywell2] 23/7/2016 01:18

b2

see olde thread for a one off post